Tag: Market Research Report

Target Protein Degradation – Transformative Approach to Selectively Eliminate Disease-Causing Protein

Targeted protein degradation is an emerging therapeutic modality that has the potential to enable the treatment of difficult-to-treat diseases. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, TPD offers a unique means to tap into the rest of the vast, unexplored proteome. Through TPD, a

Nothing Ventured, Nothing Gain: Bringing to Light The Continuous Manufacturing Equipment Providers

Over the years, several industries have implemented evolutionary changes in their respective manufacturing processes. One to the most rewarding advancements in this direction, is process automation. In pharmaceutical manufacturing, the automation of various aspects of the production process has led to the establishment of the continuous manufacturing paradigm. However, the transition to continuous manufacturing is

Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome is a condition in which the ovaries produce abnormal amount of androgens (males sex hormones), higher than the amount usually present in a woman with normal ovaries. The ovaries develop fluid filled sacs, known as follicles, which contain an immature egg. However, in polycystic ovary syndrome, none of the eggs mature and

Digital Therapeutics: Key Concepts and Regulations to Tackle COVID-19 Pandemic

Digital therapeutics are clinically validated applications / software / online programs that have demonstrated the capability to facilitate positive outcomes when used in the prevention / treatment / management of diseases / clinical conditions. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing

Inhaled and Intranasal Drug Delivery: A Deeper Look into Service Providers Landscape

The techniques used for the drug delivery are found to be have an enormous impact on the efficacy of the treatment. In fact, the slow progression of the efficacy, has suggested the need of different approaches for the effective delivery of drug to the target area, along with the optimal bioavailability. Over the years, several

Targeted Drug Delivery Devices: An Attractive Option for Improving the Efficacy of Biologics

The gradual shift of healthcare industry towards the development of biologics is a well-known fact. Owing to this shift, there are over 1,000 cell and gene therapies which are being developed for the treatment of various disorders, majority of them being oncological disorders, cardiovascular disorders and neurological disorders.  Additionally, over the last decade, multiple immunotherapies

Single-Use Bioreactors on Rescue for COVID-19 Research

The development of single-use bioreactors started nearly 40 years ago in 1980s. It was around this time that the bio-processors began to use plastic film bags to culture cells, which were initially designed for food storage and culture media containment. Moreover, incremental evolution of the concept of disposable technologies have facilitated various advancements in development

Nuclear Medicines And Radiopharmaceuticals: Redefining The Use Of Radioactivity In Modern Day Healthcare

Fostered by partnerships between national laboratories, academia, and the pharmaceutical industry, the field of nuclear medicines and radiopharmaceuticals has evolved over the past few decades, in parallel with advances in imaging instrumentation, radionuclide production, and radiopharmaceutical development. Nuclear reactors and particle accelerators are presently used to produce a wide array of radionuclides for diagnostic and

Will the Renascence of Microbial Manufacturing be Impacted by the Pandemic?

Since the discovery of recombinant DNA technology, several types of microbes have been established as a versatile biomolecule expression system. This can be attributed to the ease of handling of microbial cell lines, which are considered less fragile (compared to cells of higher eukaryotes); rendering them a popular choice for manufacturing operations. Moreover, incremental evolution

Outsourcing: An Attractive Option For Antibody Production

In recent years, contract manufacturers have become an integral part of the overall biopharmaceutical market. This trend is also gaining popularity within the antibody therapeutics market, as developers are increasingly outsourcing their antibody production requirements to contract service providers. This can be attributed to the fact that employing such third-party service providers offers various advantages,

Large Volume Wearable Injectors: A breakthrough to simplify Chronic Disease Management

The last few years have witnessed a rising incidence of chronic illnesses across the globe. Long term clinical conditions, such as neurological disorders, cardiovascular disorders, chronic pain and oncological disorders, have been shown to impose a significant burden on the modern healthcare system and those who suffer from such diseases. It is reported that about

Significant Potential of Gut Flora: Human Microbiome

Human Microbiome Therapies are Viable Alternatives to Antibiotics, with Substantial Therapeutic Potential The term microorganisms was perceived to be synonymous to harmful, disease causing agents, until the discovery of certain beneficial microbial colonies in the human system. Currently, humans and a variety of species of bacteria, yeast and protozoa, are known to co-exist in mutually

The Evolving Dynamics of Large Volume Wearable Injectors Market

The field of self-injection devices has witnessed a lot of innovation in the recent years. Specifically, , large volume wearable injectors are certainly a boon due to their ability to address challenges associated with the administration of high volume formulations, viscous drug solutions and cater to frequent dosing requirements of patients suffering from chronic health

Fill / Finish Services Industry: Impact of the Swelling Biopharmaceutical Pipelines

Biopharmaceuticals represent the most rapidly growing and high-value segment of the pharmaceutical industry. Growing at an annualized rate of ~12%, the industry stands tall with more than 5,000 biologics in development and over 300 FDA approved biologics, since 2002. Biologic drug development is characterized by high quality standards and a rapidly growing demand for novel

In Vitro ADME Testing Services: Emerging Opportunities for Service Providers

According to the US Food and Drug Administration (USFDA), less than 10% of investigational new drug (IND) candidates progress beyond the submission of a new drug application (NDA); this implies that majority of the drug / therapy candidates fail to reach the market owing to unacceptable safety and efficacy profiles and the problems associated with

Increasing Prevalence of Chronic Diseases- Driving the Demand for Self-Administration Devices, Like Autoinjectors

Over the last decade, autoinjectors have emerged as a promising therapeutic commodity for safe administration of parenteral therapies. Patients who suffer from chronic diseases, such as diabetes, rheumatoid arthritis and multiple sclerosis, often require frequent dosing of medication which poses significant inconvenience to them for visiting proper healthcare centers. Hence, autoinjector devices enable such patients

Peptide APIs – A Deeper Look Into Contract Manufacturing Market

The recent years have portrayed the renaissance of peptide APIs, as pharma industry has once again turned its attention towards the potential of therapeutic peptides. Adoption of peptides as therapeutic agents have side-lined some of the earlier concerns associated with them, such as bioavailability, and has led to manufacturing of high-quality peptides in a larger

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements

It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small

Targeted Protein Degradation is Anticipated to Become a Major Therapeutic Modality in the Coming Decade

The targeted protein degradation approach is believed to possess the potential to unlock the undruggable proteome, which was traditionally considered to be inaccessible. Compared to conventional inhibition strategies, degradation offers several benefits, which include the opportunity to completely remove aberrant proteins and associated systemic malfunctions. As a result, targeted protein degradation-based therapeutics have generated enthusiasm

In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has been witnessed. In addition to the complexities involved, the

Computational / In Silico Drug Discovery: A Boon in Disguise for Faster Drug Discovery Operations Amidst COVID-19

The COVID-19 pandemic is predicted to throw the global economy into recession, with loss of trillions of dollars. The pharmaceutical industry cannot escape the brunt of the circumstances as well. In fact, according to a survey, 95% of healthcare industry professionals are worried about the impact the pandemic is likely to have on the industry. So far,

Next Generation Immune Checkpoint Inhibitors and Stimulators: Another Big Opportunity

There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immune checkpoint inhibitors emerged as a highly specific and potent option to eradicate tumor cells with minimal side effects. Once the body

Outsourcing has become a popular trend in ophthalmic drug development domai

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of innovator companies have demonstrated a preference to outsource certain aspects of ophthalmic drug development and production operations to contract service providers. Over 240 companies

Microbiome-based Live Biotherapeutics Contract Manufacturing: Rising Opportunities for Specialized CMOs / CDMOs

What is the current development pipeline of microbiome-based live biotherapeutics? With over 85 products under preclinical and clinical development, the current development pipeline of microbiome-based live biotherapeutics has several promising candidates, which are anticipated to get commercialized over the next few years. Hence, the demand for R&D and manufacturing services for such products is anticipated

RISE OF ANTIBODY DRUG CONJUGATES WITH THE RECENT APPROVALS

Antibody drug conjugates (ADCs) have captured the attention of both large and small pharmaceutical companies, and academic / research institutions, for more than a decade. For the past few years, several failures of clinical trials were blamed for the lack of interest of some companies in this therapeutic approach. However, after a decade-long dribble of

Response to COVID-19 Pandemic with Oligonucleotides

Never before, scientists say, the universal community of researchers have put a halt to all other ongoing research and have urgently focused towards swiftly evolving health emergency. In the past few months, scientists have been repurposing their research efforts towards contributing to the global effort in response to COVID-19 pandemic. For the purpose of mitigating

Neoantigen Targeted Therapies Pave the Way to Personalized Anti-cancer Therapy

Neoantigen Targeted Therapies Pave the Way to Personalized Anti-cancer Therapy There is an urgent unmet need for developing innovative and effective cancer therapeutics for the treatment of patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, immunotherapy emerged as a highly specific and potent option to eradicate tumor

Fragment-based Drug Discovery – A Boon in Disguise to get a Breakthrough Drug Against Covid-19

With over 855,000 cases and 42,000 deaths, the novel coronavirus has taken its toll on humanity. The pandemic is predicted to throw the global economy into recession, with loss of trillions of dollars. The pharmaceutical industry cannot escape the brunt of the circumstances as well. In fact, according to a survey, 95% of healthcare industry

Synthetic Lethality Market: Riding on the ESMO 2019 Success of PARP Inhibitors

After a strong showdown at ESMO 2019, both GSK and AstraZeneca have reignited the fight of small molecule anti-cancer drugs against the industry’s brawny immunotherapy push. Leading this fight is poly(ADP-ribose) polymerase (PARP) inhibitor, one of the leading synthetic lethality targets. These better than expected results at ESMO further validate the potential of synthetic lethality

Antibody Discovery: The Rise of Services and Platform Providers

The rising demand for personalized medicines to provide targeted treatment options has encouraged pharmaceutical companies to shift their focus from small molecules to discovery and development of biologics, particularly antibody-based therapeutics. The ‘Antibody Discovery: Services and Platforms, 2017-2027’ report provides an extensive study on the current market landscape and future outlook of the antibody discovery service and

Large Volume Wearable Injectors: The Goldrush Continues

The large scale adoption of prefilled syringes demonstrated the growing interest in the concept of such convenient drug delivery systems. Large volume wearable injectors are advanced versions of the existing self-injection devices. The ‘Large Volume Wearable Injectors Market (3rd Edition), 2017-2027′ report features an extensive study of the current landscape and the likely future evolution of this category